Neck Relax Reviews – Best Neck Massager around? – Product Review by Mike Vaughn
See the rest here:
Neck Relax Reviews – Best Neck Massager around? – Product Review by Mike Vaughn
Author Archives: admin
Global Gene Therapy Market Report 2020-2030 Featuring Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics, Voyager Therapeutics,…
DUBLIN, Dec. 17, 2020 /PRNewswire/ -- The "Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global gene therapy market market.
Major players in the gene therapy market are Novartis AG, Bluebird Bio, Inc., Spark Therapeutics, Inc., Audentes Therapeutics, Voyager Therapeutics, Applied Genetic Technologies Corporation, UniQure N.V., Celgene Corporation, Cellectis S.A. and Sangamo Therapeutics.
The global gene therapy market is expected to decline from $3.22 billion in 2019 to $3.18 billion in 2020 at a compound annual growth rate (CAGR) of -1.30%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The market is then expected to recover and reach $6.84 billion in 2023 at a CAGR of 29.09%.
The gene therapy market consists of sales of gene therapy related services by entities (organizations, sole traders and partnerships) that manufacture gene therapy drugs. Gene therapy is used to replace faulty genes or add new genes to cure disease or improve the body's ability to fight disease. Only goods and services traded between entities or sold to end consumers are included.
North America was the largest region in the gene therapy market in 2019.
The gene therapy market covered in this report is segmented by gene type into antigen; cytokine; suicide gene; others. It is also segmented by vector into viral vector; non-viral vector; others, by application into oncological disorders; rare diseases; cardiovascular diseases; neurological disorders; infectious diseases; others, and by end users into hospitals; homecare; specialty clinics; others.
In December 2019, Roche, a Switzerland-based company, completed its acquisition of Spark Therapeutics for $4.3 billion. With this deal, Roche is expected to strengthen its presence in the gene therapy segment, support transformational therapies and increase its product portfolio. Spark Therapeutics is a US-based company involved in gene therapy.
The high prices of gene therapy medicines are expected to limit the growth of the gene therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer and other diseases has influenced the health conditions of the population and has led to a low average life expectancy.
Luxturna, a one-time treatment for acquired retinal eye disease, costs $850,000 in the US and 613,410 in the UK, despite a markdown that is applied through Britain's National Health Service. Zolgensma, for spinal muscular atrophy, is valued at $2.1 million in the US and Zynteglo, which focuses on a rare genetic blood disorder, costs $1.78 million, thus restraining the growth of the market.
The use of machine learning and artificial intelligence is gradually gaining popularity in the gene therapy market. Artificial intelligence (AI) is the simulation of human intelligence in machines, which are programmed to display their natural intelligence. Machine learning is a part of AI.
Machine learning and AI help companies in the gene therapy market to conduct a detailed analysis of all relevant data, provide insights between tumor and immune cell interactions, and offer a more accurate evaluation of tissue samples often conflicted between different evaluators. For instance, since January 2020, GlaxoSmithKline, a pharmaceutical company, has been investing in AI to optimize gene therapy and develop off-the-shelf solutions for patients. It is also expected to reduce turnaround time and also the cost of gene therapies.
Key Topics Covered:
1. Executive Summary
2. Gene Therapy Market Characteristics
3. Gene Therapy Market Size And Growth 3.1. Global Gene Therapy Historic Market, 2015 - 2019, $ Billion 3.1.1. Drivers Of The Market 3.1.2. Restraints On The Market 3.2. Global Gene Therapy Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion 3.2.1. Drivers Of The Market 3.2.2. Restraints On the Market
4. Gene Therapy Market Segmentation 4.1. Global Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.2. Global Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.3. Global Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.4. Global Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Gene Therapy Market Regional And Country Analysis 5.1. Global Gene Therapy Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion 5.2. Global Gene Therapy Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/fltbmv
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets Laura Wood, Senior Manager [emailprotected]
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
http://www.researchandmarkets.com
Read more from the original source:
Global Gene Therapy Market Report 2020-2030 Featuring Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics, Voyager Therapeutics,...
Gene Therapy Market Worth USD 35.67 Billion at 33.6% CAGR; Rising Prevalence of Spinal Muscular Atrophy to Augment Growth: Fortune Business Insights -…
December 14, 2020 08:07 ET | Source: Fortune Business Insights
Pune, India, Dec. 14, 2020 (GLOBE NEWSWIRE) -- The report mentions that the Gene Therapy Market size was USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, exhibiting a CAGR of 33.6% during the forecast period. The global gene therapy market is set to gain momentum from the rising incidence of different types of cancer. The field of this therapy is undergoing several technological advancements that would help in treating cancer in those patients who are at high risks of getting affected by this disease through genetic mutations. In 2019, the U.S. generated USD 2.16 billion in terms of revenue. The country is expected to dominate throughout the coming years stoked by the increasing usage of advanced gene therapies for the treatment of rare conditions.
KEY INDUSTRY DEVELOPMENTS:
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/gene-therapy-market-100243
Increasing Innovations & Research Activities to Boost Growth
The U.S Food and Drug Administration (FDA) stated that it is expecting to receive more than 200 applications of this therapy by the end of 2020. This showcases that the rising number of research studies and innovations in this field would affect the gene therapy market growth positively in the near future. In North America, almost 208 companies are currently operating in this market. In addition to this, the Alliance for Regenerative Medicine declared that as of 2018, approximately 259 potential drug candidates are under Phase I clinical trials across the globe.
However, the outbreak of the COVID-19 pandemic is presently impacting the field of research. According to the director of the Office of Tissues and Advanced Therapy (FDA) named Wilson Brayan, nowadays the officials are prioritizing only those drugs that are associated with coronavirus.
To get to know more about the short-term & long-term impact of COVID-19 on this market, please click here: https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243
The U.S. to Dominate Owing to Presence of Favorable Policies
In 2019, the U.S. generated USD 2.16 billion in terms of revenue. The country is expected to dominate throughout the coming years stoked by the increasing usage of advanced gene therapies for the treatment of rare conditions.
Besides, the presence of favorable reimbursement policies and guidelines would also help in propelling the market growth here. As this type of treatment is not legal in several developing nations, industry giants are emphasizing on the U.S. for launching their products.
Europe, on the other hand, is anticipated to grow significantly backed by the adoption of unique treatment options. Asia Pacific is set to hold a comparatively lower share on account of the decreasing usage of gene therapy because of its expensive nature.
Quick Buy - Gene Therapy Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100243
List of Key Players operating in Gene Therapy Market:
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/gene-therapy-market-100243
Global Gene Therapy Market Segmentations:
By Application
Oncology
Neurology
Others
By Vector Type
Viral
Non-viral
By Distribution Channel
Hospitals
Clinics
Others
By Geography
U.S.
Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
Asia-Pacific (Japan, China, and Rest of Asia- Pacific)
Rest of World
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/gene-therapy-market-100243
SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:
Have a Look at Related Reports:
India Peritoneal Dialysis Market Share & Industry Analysis, By Type (Continuous Ambulatory Peritoneal Dialysis (CAPD), Automated Peritoneal Dialysis (APD)), By Product (Devices (Cyclers/Machines), PD Solutions/Fluids, PD Sets, Catheters) Forecast, 2019-2025
Guidewire Market Share & Industry Analysis, By Product (Coronary Guidewire, Peripheral Guidewire, Urology Guidewire, Neurovascular Guidewire, and Others) By Material (Nitinol, Stainless Steel, and Others) By Coating (Coated and Non-Coated) By End User (Hospitals & Clinics, Diagnostic Centers, and Others) and Regional Forecast, 2019-2026
India Insulin Pumps Market Share & Industry Analysis, By Product (Insulin Pumps (Tethered Pumps and Patch Pumps) and Consumables (Reservoirs, Infusion Sets, and Others) and Region Forecast, 2019-2025
Lactose Market Share Trends & Industry Analysis, By Purity (Crude Lactose, Edible Lactose, and Refined-edible Grade Lactose), By Color (Yellow Lactose, Pale-yellow to White Lactose, and White Lactose), By Applications (Food, Feed, Infant Formula, and Pharmaceuticals), and Regional Forecast, 2019-2026
Contact Lenses Market Share & Industry Analysis, By Modality (Reusable and Disposable), By Design (Toric, Multi-focal, and Spherical), By Distribution Channel (Retail Stores, Online Stores, and Ophthalmlogists), and Regional Forecast, 2019-2026
About Us:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.
Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: sales@fortunebusinessinsights.com Fortune Business Insights LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/global-gene-therapy-market-10136
Worldwide Industry for Cystic Fibrosis Therapeutics to 2025 – Players Include AbbVie, Alaxia and Alcresta Therapeutics Among Others – Stockhouse
Dublin, Dec. 17, 2020 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
The global cystic fibrosis therapeutics market grew at a CAGR of around 15% during 2014-2019. Cystic fibrosis (CF) is a rare and progressive genetic disorder that is characterized by an abnormal movement of sodium and chloride across the gastrointestinal and respiratory tracts. This disorder can cause the development of viscous secretions in the lungs, pancreas, intestines and liver. The management and treatment of CF involve physical therapy, gene therapy, physiotherapy and nutritional support. Along with this, gene therapy and medicinal drugs, such as pancreatic enzyme supplements, mucolytics, bronchodilators and cystic fibrosis transmembrane conductance regulator (CFTR) modulators are also used for targeting cellular interactomes and symptomatic improvement. These drugs can be administered to the patient orally or by inhalation.
The rising incidence of cystic fibrosis across the globe, along with improvements in the diagnostic technologies of the disorder, is one of the key factors driving the growth of the market. Furthermore, widespread adoption of cystic fibrosis transmembrane conductance (CFTR) modulators as a treatment alternative is also providing a boost to the market growth. CFTRs are configured to regulate the flow of water and chloride through cell linings of the lungs and other organs and correct the malfunctioning protein in the body.
Additionally, various technological advancements, such as the development of personalized drug therapy, molecular prosthetics and innovative drugs with improved efficacy, are acting as another growth-inducing factor. Other factors, including rising healthcare expenditures, increasing health consciousness, and awareness regarding the available treatment options for cystic fibrosis, are projected to drive the market further. Looking forward, the publisher expects the market to continue to exhibit strong growth during 2020-2025.
Breakup by Drug Class:
Breakup by Drug Molecule Type:
Breakup by Route of Administration:
Breakup by End-User:
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alaxia, Alcresta Therapeutics Inc., Allergan, AstraZeneca, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., etc.
Key Questions Answered in this Report:
Key Topics Covered:
1 Preface
2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction 4.1 Overview 4.2 Key Industry Trends
5 Global Cystic Fibrosis Therapeutics Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Forecast
6 Market Breakup by Drug Class 6.1 Pancreatic Enzyme Supplements 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Mucolytics 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Bronchodilators 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 CFTR Modulators 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Antibiotics 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Others 6.6.1 Market Trends 6.6.2 Market Forecast
7 Market Breakup by Drug Molecule Type 7.1 Small Molecule Drugs 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Biologics 7.2.1 Market Trends 7.2.2 Market Forecast
8 Market Breakup by Route of Administration 8.1 Oral Drugs 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Inhaled Drugs 8.2.1 Market Trends 8.2.2 Market Forecast
9 Market Breakup by End-User 9.1 Hospitals 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Clinics 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Others 9.3.1 Market Trends 9.3.2 Market Forecast
10 Market Breakup by Region 10.1 North America 10.1.1 United States 10.1.1.1 Market Trends 10.1.1.2 Market Forecast 10.1.2 Canada 10.1.2.1 Market Trends 10.1.2.2 Market Forecast 10.2 Asia Pacific 10.2.1 China 10.2.1.1 Market Trends 10.2.1.2 Market Forecast 10.2.2 Japan 10.2.2.1 Market Trends 10.2.2.2 Market Forecast 10.2.3 India 10.2.3.1 Market Trends 10.2.3.2 Market Forecast 10.2.4 South Korea 10.2.4.1 Market Trends 10.2.4.2 Market Forecast 10.2.5 Australia 10.2.5.1 Market Trends 10.2.5.2 Market Forecast 10.2.6 Indonesia 10.2.6.1 Market Trends 10.2.6.2 Market Forecast 10.2.7 Others 10.2.7.1 Market Trends 10.2.7.2 Market Forecast 10.3 Europe 10.3.1 Germany 10.3.1.1 Market Trends 10.3.1.2 Market Forecast 10.3.2 France 10.3.2.1 Market Trends 10.3.2.2 Market Forecast 10.3.3 United Kingdom 10.3.3.1 Market Trends 10.3.3.2 Market Forecast 10.3.4 Italy 10.3.4.1 Market Trends 10.3.4.2 Market Forecast 10.3.5 Spain 10.3.5.1 Market Trends 10.3.5.2 Market Forecast 10.3.6 Russia 10.3.6.1 Market Trends 10.3.6.2 Market Forecast 10.3.7 Others 10.3.7.1 Market Trends 10.3.7.2 Market Forecast 10.4 Latin America 10.4.1 Brazil 10.4.1.1 Market Trends 10.4.1.2 Market Forecast 10.4.2 Mexico 10.4.2.1 Market Trends 10.4.2.2 Market Forecast 10.4.3 Others 10.4.3.1 Market Trends 10.4.3.2 Market Forecast 10.5 Middle East and Africa 10.5.1 Market Trends 10.5.2 Market Breakup by Country 10.5.3 Market Forecast
11 SWOT Analysis 11.1 Overview 11.2 Strengths 11.3 Weaknesses 11.4 Opportunities 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis 13.1 Overview 13.2 Bargaining Power of Buyers 13.3 Bargaining Power of Suppliers 13.4 Degree of Competition 13.5 Threat of New Entrants 13.6 Threat of Substitutes
14 Price Indicators
15 Competitive Landscape 15.1 Market Structure 15.2 Key Players 15.3 Profiles of Key Players 15.3.1 Abbvie Inc. 15.3.1.1 Company Overview 15.3.1.2 Product Portfolio 15.3.1.3 Financials 15.3.1.4 SWOT Analysis 15.3.2 Alaxia 15.3.2.1 Company Overview 15.3.2.2 Product Portfolio 15.3.3 Alcresta Therapeutics Inc. 15.3.3.1 Company Overview 15.3.3.2 Product Portfolio 15.3.4 Allergan 15.3.4.1 Company Overview 15.3.4.2 Product Portfolio 15.3.4.3 Financials 15.3.4.4 SWOT Analysis 15.3.5 AstraZeneca 15.3.5.1 Company Overview 15.3.5.2 Product Portfolio 15.3.5.3 Financials 15.3.5.4 SWOT Analysis 15.3.6 F. Hoffmann-La Roche Ltd 15.3.6.1 Company Overview 15.3.6.2 Product Portfolio 15.3.7 Gilead Sciences Inc. 15.3.7.1 Company Overview 15.3.7.2 Product Portfolio 15.3.7.3 Financials 15.3.7.4 SWOT Analysis 15.3.8 Merck & Co., Inc. 15.3.8.1 Company Overview 15.3.8.2 Product Portfolio 15.3.8.3 Financials 15.3.8.4 SWOT Analysis 15.3.9 Novartis AG 15.3.9.1 Company Overview 15.3.9.2 Product Portfolio 15.3.9.3 Financials 15.3.9.4 SWOT Analysis 15.3.10 Teva Pharmaceutical Industries Ltd. 15.3.10.1 Company Overview 15.3.10.2 Product Portfolio 15.3.10.3 Financials 15.3.10.4 SWOT Analysis 15.3.11 Vertex Pharmaceuticals Inc. 15.3.11.1 Company Overview 15.3.11.2 Product Portfolio 15.3.11.3 Financials 15.3.11.4 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/jx25ft
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
See original here:
Worldwide Industry for Cystic Fibrosis Therapeutics to 2025 - Players Include AbbVie, Alaxia and Alcresta Therapeutics Among Others - Stockhouse
Elidah Becomes the Only US Company to Win a Top Ten Prize in a Global Start-up Competition, Advancing Recognition for Women’s Health – PRNewswire
MONROE, Conn., Dec. 16, 2020 /PRNewswire/ --Elidah, maker of ELITONE, a home-use treatment for incontinence, announced it was selected out of 7500 entries from 159 countries to win a Top Ten award from the global SLINGSHOT 2020 start-up competition. Elidah was the only company from the United States awarded this distinction, and one of two start-ups in the life science category.Normally held in Singapore,this year the event was virtual and offered a record $750,000 in cash prizes by StartUpSG. One hundred companies pitched at the live event, and from those ten finalists were selected. The award winners included start-ups from all over the world including Israel, United Kingdom, Singapore, and India, among others.
"We sometimes have the mindset that successful start-ups must come from Silicon Valley," said Gloria Kolb, co-founder and CEO of Elidah, "but innovation is flourishing in the rest of the world as entrepreneurial support systems expand. I was impressed by the other finalists, advancing technologies such as biometric security, artificial intelligence, and gene editing." Although the top prize went to another start-up, Ms. Kolb, as the only female entrepreneur in the finals, was happy to see a company focused on women's health receive recognition. "Women's health should not be a taboo subject, and I hope that investors realize it presents a large market, ripe for innovation."
ELITONE is the first home-health device that performs the hard-to-do pelvic floor exercises for women. It operates externally, without the invasiveness of vaginal probes. Exercises are needed to tone the pelvic floor muscles, but they can be hard to do correctly. The wearable nature of ELITONE allows women to do other activities while getting treatment at home, saving time, cost, and risk of infection. In a time when the clinics and pelvic floor physical therapy offices have shut down, at-home over-the-counter devices like ELITONE provide much-needed access to effective FDA-cleared treatments.
About Elidah
Elidah is a women-owned FemTech company established to develop technologies that integrate recent advances in wearable devices, biomaterials, and mobile interfaces to deliver innovative therapeutic solutions.Elidah is led by entrepreneur Gloria Kolb, Founder and CEO, an MIT and Stanford trained engineer whose previous accolades include Boston's 40 under 40 and MIT Technology Review's World Top Innovators Under 35 (TR35). To learn more visit elitone.com.
Contact: Gloria Kolb [emailprotected] 810 Main St., Ste C, Monroe, CT 06468 978-435-4324
SOURCE Elidah
Explained: Process of transporting stem cell from donor to patient for a successful transplant – Firstpost
Patrick PaulDec 17, 2020 15:08:12 IST
A successful stem cell transplant from a matching blood stem cell donor can be lifesaving for patients who suffer from diseases like blood cancer, Thalassemia or Aplastic Anemia. Finding a matching stem cell donor is only half the battle and it is also equally important for the stem cells of the donor to actually reach the patient on time as delays in transplant can be life-threatening for a patient. Blood stem cells are collected from a donor in the same way a blood platelet donation is done.
But what happens to the stem cells after it has been collected from a donor?
Deepika is a donor from DKMS BMST registry who has successfully donated her blood stem cells for a patient suffering from blood cancer. Image credit: DKMS BMST Foundation India
Once a potential donor comes up as a match for a patient, the blood stem cells are collected via peripheral blood stem cell collection method, post which the medical team waits for the stem cell count from the laboratory. The amount of stem cell count which is to be collected from a donor is related to the number of stem cells required by the recipient. The stem cells cannot be released for transport unless the stem cell count has been sent from the lab and clearance has been given from the Collection centre physician.
The stem cells are stored at 2-8 degrees Celsius after the collection. As per the World Marrow Donor Association (WMDA) guidelines, the product must be transported between +1-10 degree Celsius and the viability of the stem cells between said temperatures is 72 hours.
The stem cells are transported in a special package called a Credo Box that is prepped in advance to 4 degrees Celsius. The credo box maintains a temperature of 2-8 degrees Celsius for 100 hours. There are two temperature loggers on this box that records the temperature of the inside of the box every 15 minutes.
The transportation of stem cells is a carefully guided process that takes precision and training by the courier personnel. An interesting fact is that only a human courier can carry the product. The reason for this is that the viability of stem cells is 72 hours, which means that once the patient has been conditioned or their body has been prepped for a transplant, their immunity is very low. They should receive a transplant within that time frame or the consequences can be life-threatening. Therefore, it is extremely critical for the stem cells to be securely transported and delivered to the Transplant Centre within this timeframe.
Blood stem cells are collected from a donor in the same way a blood platelet donation is done. Image credit: Wikipedia
Some guidelines followed while transporting blood stem cells are:
The process differs for domestic and international transplants. If the stem cells is for the international Transplant centre, the Transplant centre decides for the transport of the product. If the product is for a national Transplant centre, the local stem cell registry is responsible for the transport of the product from the Collection Centre to the Transplant Center.
After the product reaches the Transplant centre, it is brought back up to room temperature and infused into the patient. If the donor has consented to cryopreservation, then the product is cryopreserved and infused at the later date. With cryopreservation on -80 degree Celsius on carbon dioxide or -196 degree Celsius on liquid nitrogen blood stem cells can be stored for a long time.
The stem cells are transported in a special package called a Credo Box that is prepped in advance to 4 degrees Celsius and maintains a temperature of 2-8 degrees Celsius for 100 hours. Image credit: Wikipedia
The COVID-19 pandemic created a lot of challenges concerning blood stem cell donations due to the closing of borders, travel restrictions, quarantine guidelines, etc. Stem cell registries like DKMS-BMST came up with a unique solution of transporting the products without courier personnel but via the pilot in the cockpit. The product was handed over to the pilot via a courier at the airport, and the pilot would take the product into the cockpit. This also meant that most of the planes could be utilized, even cargo planes without constraints of flight schedules.
With rising blood cancer cases in India, a successful blood stem cell donation from a matching donor can help blood cancer patients receive a second chance at life. The first step to ensuring this is that people are aware of the process of blood stem cell donation and register as a potential blood stem cell donor!
The author is the CEO of the NGO DKMS BMST Foundation, India
Go here to see the original:
Explained: Process of transporting stem cell from donor to patient for a successful transplant - Firstpost
Research That Saves Lives: Four COVID-19 Therapies Being Tested at UVA – University of Virginia
Regeneron: Preventing Infection Among Households
Regeneron: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2
In this multisite trial, researchers are working to determine if monoclonal antibodies made by the drug company Regeneron Pharmaceuticals can prevent COVID-19 infection among people who have been exposed by someone in their household, but have not yet developed the disease. The trial is testing the same antibody cocktail given to President Donald Trump when he was hospitalized with COVID-19, though with a different use.
In this case, the antibodies are intended to prevent people from getting sick if they have a household member with COVID, Enfield said. So far, UVA has done a good job with recruitment, which is particularly tricky in this case as you have to find people who have been exposed to COVID in their household, but who do not yet have COVID.
UVA is recruiting 40 participants for the study, each of whom will receive four injections of either the antibodies or a placebo. Participants must have been exposed to COVID-19 by someone in their household within the previous 96 hours and continue to live with that person for a month.
Its been a rapid process, and a testament to the multidisciplinary team involved, from infectious disease clinicians and researchers to cell therapy, pulmonary critical care and several other departments, Sturek said. Its been all-hands-on-deck.
As results from these and other clinical trials continue to come in, Sturek also expressed hope that we will see widespread and effective vaccine distribution sooner, rather than later.
There is a lot on the horizon, from news around vaccines to getting the first wave of vaccines to high-risk people like health care workers, he said. Every day we learn something new, and its important to stay humble, to be able to adapt and change on the fly.
Fighting this pandemic has been a huge, multidisciplinary effort, and so many people joined in to help contribute and bring new treatments to our patients, and bring new research to the field. That doesnt get done without a huge team of nurses, clinical research coordinators, pharmacists, respiratory therapists and many, many others. It is impossible to overstate the importance of all of that teamwork.
Link:
Research That Saves Lives: Four COVID-19 Therapies Being Tested at UVA - University of Virginia
Even if You’ve Had COVID-19 You Still Need the Vaccine – Healthline
COVID-19 is currently the leading cause of death in the United States killing more people each day than heart disease or cancer.
To help stem the tide of this life-threatening disease, scientists around the world have been working to develop vaccines.
Last week, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the first of these vaccines, developed by Pfizer and BioNTech.
The EUA allows for the distribution of the Pfizer-BioNTech COVID-19 vaccine across the United States. This vaccine has been developed to prevent COVID-19 in people age 16 years and older.
Getting 2 doses of the vaccine may drastically reduce your chances of developing COVID-19.
Even if youve had COVID-19, getting the vaccine may help prevent reinfection and lower your risk of getting sick again.
Were really happy to have a safe and effective tool [against COVID-19], Dr. Iahn Gonsenhauser, chief quality and patient safety officer at The Ohio State University Wexner Medical Center in Columbus, Ohio, told Healthline.
Were encouraging everybody to explore their opportunity to access the COVID vaccine as soon as thats made available to them, he said.
When someone develops COVID-19, their immune system learns to recognize the virus and begins to produce antibodies to fight against it.
If that person recovers from the disease, they may have immunity against reinfection with the virus for a period of time afterwards.
However, questions remain about how long that immunity lasts.
We dont know how long the immunity triggered by infection persists, and someone infected in the spring may no longer be immunologically protected now in December, Dr. David Hirschwerk, an infectious disease specialist at Northwell Health in Manhasset, New York, told Healthline.
It does stand to reason that somebody with COVID-19 infection is likely immune for 3 to 4 months at least, he said, but we dont have firm data to support this yet.
Cases of reinfection with the virus that causes COVID-19 have been reported.
Getting vaccinated may help to strengthen immunity against COVID-19.
In an ongoing clinical trial, Pfizer and BioNTech have studied their vaccine in people with and without a history of exposure to the virus.
Their research to date has found the vaccine is 95 percent effective at preventing COVID-19.
Their findings suggest it may help prevent reinfection in people who have already been exposed to the virus, as well as lowering the risk of infection in people with no history of exposure.
Data from the phase 2/3 trial for the Pfizer-BioNTech vaccine suggest that the vaccine is safe and likely effective in persons with previous evidence of SARS-CoV-2 infection, said Dr. Miriam Smith, chief of infectious disease at Long Island Jewish Forest Hills in Queens, New York.
[The] vaccine should be offered to all persons regardless of history of prior symptomatic or asymptomatic infection, she said.
The Centers for Disease Control and Prevention (CDC) currently advises that people with a known history of COVID-19 may wait up to nearly 90 days after their prior infection to get vaccinated, if they prefer to do so.
While more research is needed, available evidence suggests that reinfection with this virus is rare within 90 days of initial infection.
If someone currently has active symptoms of COVID-19, the CDC recommends they wait to get vaccinated until theyve recovered and met the criteria for ending isolation.
The Pfizer-BioNTech COVID-19 vaccine carries some risk of side effects.
However, ongoing research suggests the side effects tend to be mild and short-lived.
The way that we generally approach these questions in healthcare is through risk-benefit analysis, Gonsenhauser said.
In this case, the risk of some adverse response to the vaccine is low, and the benefit of knowing that you have a potentially extended or refreshed immunity to COVID is significant, he said.
With that, were recommending that people get the vaccine, even if theyve already had a COVID exposure and infection, he continued.
The most commonly reported side effect associated with the Pfizer-BioNTech COVID-19 vaccine is pain around the injection site.
Some people who received the vaccine developed other side effects such as fatigue, headache, and muscle aches, which tend to resolve within a day or so.
The risk of severe adverse events following the vaccine appears to be very low. However, some groups of people might face higher risk of adverse reactions than others.
For example, if you have a history of severe allergic reaction to any of the ingredients contained in the vaccine, the FDA recommends that you not receive it.
Talk with your doctor to learn more about the potential benefits and risks of getting vaccinated against COVID-19.
Read more here:
Even if You've Had COVID-19 You Still Need the Vaccine - Healthline
Physio Logic Brings Cutting-edge Regenerative Treatments for Sport Injuries and Arthritis to New York City – PRNewswire
NEW YORK, Dec. 17, 2020 /PRNewswire/ -- Physio Logic, a leading provider of integrated health services in New York City and surrounding areas, continues to demonstrate its commitment to excellence in the field of Regenerative Medicine and Stem Cell Therapy by entering into a collaboration with Regenexx, a worldwide network of specially trained physicians providing the world's most advanced, research-driven, regenerative medicine and stem cell therapy treatments. The partnership brings cutting-edge regenerative treatments to New York City residents suffering from sports injuries or degenerative diseases.
The Regenerative Medicine division of Physio Logic is led by Dr. Tanuj Palvia, MD, a specialist in regenerative medicine and interventional orthopedics focused on the treatment of musculoskeletal injuries and degenerative orthopedic conditions.
"Stem Cell Therapy is one of the most innovative treatments available today but, being so new, patients need to know they're receiving the best possible care. As a physician, I hold myself and my practice to the highest standards and, being aligned with Regenexx adds that extra assurance patients need to know they're in good hands. Whether it's a nagging sports injury or slow degeneration, you're going to get the highest quality of integrated care right here at Physio Logic," said Dr. Palvia.
Interventional Orthobiologics is a specialty that focuses on using your body's natural healing agents to treat orthopedic injuries with the goal of reducing pain and improving joint function. The variety of orthobiologics available to Regenexx physicians, such as bone marrow stem cells and platelet-rich plasma (PRP), allow them to create a treatment plan to best support your recovery. It can be used in the treatment of conditions such as arthritis and injury to ligaments, tendons, cartilage, or bone.
"Being selected to represent the Regenexx brand in New York City speaks to the quality of our facility, our providers, and the care we give our patients," said Dr. Rudy Gehrman, CEO & Founder of the Brooklyn based clinic. "Physio Logic is raising the standard of healthcare in New York and our partnership with Regenexx is an extension of the quality, integrative care we provide to every patient that walks through our door."
Regenexx physicians are required to have thousands of hours of experience performing precise, injection-based treatments using image guidance for a range of body parts and injuries. Their strict acceptance criteria means that Regenexx only chooses the most qualified physicians to join their network. Physio Logic's Interventional Pain Specialist, Dr. Tanuj Palvia, MD, is ranked among them.
To learn more about Physio Logic and Regenerative Medicine, go to https://physiologicnyc.com/regenerative-medicine/
About Physio Logic Physio Logic brings together an expert team of open-minded medical doctors, physical therapists, chiropractors, acupuncturists, massage therapists, nutritionists, health coaches, biohackers, and Pilates instructors. Our unique collaborative approach, coupled with our ability to assess patients holistically, is used to create a custom care plan tailored to patients' needs. For more information on Physio Logic, visit https://physiologicnyc.com or call (718) 260-1000.
About Regenexx Regenexx is a nationwide network of physicians who practice Interventional Orthopedics, a new specialty that focuses on using the most advanced regenerative protocols available as an alternative to many orthopedic surgeries. Regenexx has published roughly half of the research worldwide on the use of orthobiologics for treating orthopedic injuries, and our patented treatment lab-processing and treatment protocols allow us to achieve unmatched results. Our procedures use your body's natural healing agents including blood platelets and bone marrow concentrate to repair damaged bone, muscle, cartilage, tendons and ligaments. For more information on Regenexx, visit https://regenexx.com.
Media contact: Alan Sott [emailprotected] (718) 260-1000
SOURCE Physio Logic
Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using…
OCEANSIDE, Calif., Dec. 17, 2020 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of an Investigational New Drug (IND) application seeking permission from the Food and Drug Administration (FDA) to initiate a Phase I/II clinical trial assessing safety and signals of efficacy for treatment of Chronic Traumatic Encephalopathy (CTE) patients with JadiCells.
The JadiCell is a type of umbilical cord derived mesenchymal stem cell which possesses superior therapeutic activity as compared to other stem cell types based on laboratory and clinical studies. The JadiCell was recently reported to possess therapeutic activity against COVID-19 in a recently published clinical trial1. The Company previously obtained an exclusive license for use of JadiCells for CTE and Traumatic Brain Injury (TBI)2,3.
"My team and myself are extremely excited about the potential of using our unique novel cell therapy for treatment of CTE, which is the cause of countless deaths, as well as chronic disabilities" said Dr. Amit Patel, inventor of the JadiCell. "Having worked over the past several years with the multidisciplinary team assembled by Timothy Dixon, I look forward to progress in this area of medicine, for which currently there are limited options."
Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players4. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells.
Suicide is a major cause of death in military veterans, approximately 20 deaths per day5. It is widely known that TBI and CTE are associated with increased propensity for suicide6,7. Furthermore, studies show that cytokines associated with brain inflammation, such as IL-6 and TNF-alpha are found in higher levels in patients with suicidal tendencies8.
"To our knowledge, this is the first therapeutic intervention addressing CTE using stem cells and we are tremendously excited to finally move into clinical testing for this terrible disease that not only affects athletes but our military and law enforcement as well" said Timothy Dixon, President and CEO of the Company. "Having worked over the last 2 years in developing the preclinical data supporting this IND, we are extremely pleased to file this new drug application today."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is http://www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.comand Campbell Neurosciences at https://www.campbellneurosciences.com
1https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696875
2https://www.globenewswire.com/news-release/2019/07/01/1876699/0/en/Therapeutic-Solutions-International-2Obtains-Exclusive-License-for-Patented-Clinical-Stage-Adult-Stem-Cell-for-Treatment-of-Military-and-Sports-Brain-Injuries.html
3https://patents.google.com/patent/US9803176?oq=9803176
4https://www.nytimes.com/interactive/2017/07/25/sports/football/nfl-cte.html
5https://en.wikipedia.org/wiki/United_States_military_veteran_suicide
6https://www.psychcongress.com/news/traumatic-brain-injury-tied-increased-risk-suicide
7https://sbindependent.org/nfl-athletes-with-cte-who-committed-suicide/
8https://www.ncbi.nlm.nih.gov/pubmed/20951793
[emailprotected]
SOURCE Therapeutic Solutions International
therapeuticsolutionsint.com
Continue reading here:
Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using...